🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSOUL trial preliminary data — November 2025 Page 6

SOUL trial preliminary data — November 2025

JenMemphis Sun, Mar 16, 2025 at 2:50 AM 51 replies 2,130 viewsPage 6 of 11
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Mar 25, 2025 at 5:23 AM#26
Dr.ObesityMed said:
It helps to say which part of this you are uncertain about.

There is a second half to this that has not been said yet. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

9 7kim_atl_prep, sarah_TO, wendy_avl and 6 others
Reply Quote Save Share Report
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Mar 26, 2025 at 1:16 AM#27

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

Last edited: Mar 26, 2025 at 2:16 AM
10 8Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 7 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Mar 26, 2025 at 9:09 PM#28

Following on from Dr.ObesityMed — and this may be the naive question:

Was that from a primary source or from a summary of one?

11 9AmyNC_wife, SkepticalSean, Dr.CardioMD and 8 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
emma_london
Member
312
1,456
Oct 2024
London, UK
Mar 27, 2025 at 5:01 PM#29
BiostatsBrad said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

Last edited: Mar 27, 2025 at 11:01 PM
12 10JessicaM_2024, TomFromTexas, mike.trainer_LA and 9 others
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Mar 28, 2025 at 12:53 PM#30

Closing the loop on my own question.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.

Last edited: Mar 28, 2025 at 5:53 PM
34 7LarryQC_SD, wanda_boise, NurseAsh_DET and 31 others
Reply Quote Save Share Report
14567811

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register